Investors focused on the Medical space have likely heard of Bio-Rad Laboratories (BIO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of BIO and the rest of the Medical group's stocks.
Bio-Rad Laboratories is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BIO is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BIO's full-year earnings has moved 8.12% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that BIO has returned about 25.48% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.84% on average. This means that Bio-Rad Laboratories is outperforming the sector as a whole this year.
Looking more specifically, BIO belongs to the Medical - Products industry, a group that includes 70 individual stocks and currently sits at #100 in the Zacks Industry Rank. On average, this group has gained an average of 11.30% so far this year, meaning that BIO is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BIO. The stock will be looking to continue its solid performance.